浙江京新药业股份有限公司 关于归还募集资金的公告

Core Points - Zhejiang Jingxin Pharmaceutical Co., Ltd. has approved the temporary use of idle raised funds to supplement working capital, not exceeding 290 million yuan [1] - The funds include 90 million yuan from the 2016 non-public offering and 200 million yuan from the 2020 non-public offering, with a usage period of up to 12 months [1] - As of March 21, 2025, the company has fully returned the 90 million yuan from the 2016 offering to the designated account, which was subsequently closed on April 7, 2025 [2] - By August 13, 2025, the company has also returned the 200 million yuan from the 2020 offering to the designated account, totaling 290 million yuan returned [2] Summary by Sections - Company Announcement: The company held its eighth board meeting on August 14, 2024, to approve the temporary use of idle funds [1] - Fund Return Status: The company has successfully returned all raised funds to the designated account within the stipulated time frame [2] - Closure of Accounts: The designated account for the 2016 offering was officially closed after all funds were utilized [2]